AIM ImmunoTech Inc.
AIM
$1.47
$0.075.00%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -25.71% | -50.00% | -60.00% | -30.77% | -23.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.71% | -50.00% | -60.00% | -30.77% | -23.91% |
| Cost of Revenue | 750.00% | 25.00% | 25.00% | -41.67% | -73.33% |
| Gross Profit | -255.56% | -64.29% | -81.25% | -28.30% | 68.75% |
| SG&A Expenses | -41.60% | -42.61% | -32.25% | -60.59% | -43.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.34% | -28.66% | -37.05% | -58.06% | -44.85% |
| Operating Income | 45.49% | 28.37% | 36.89% | 58.19% | 44.97% |
| Income Before Tax | 11.24% | -52.18% | 36.31% | 52.55% | 52.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.24% | -52.18% | 36.31% | 52.55% | 52.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.24% | -52.18% | 36.31% | 52.55% | 52.66% |
| EBIT | 45.49% | 28.37% | 36.89% | 58.19% | 44.97% |
| EBITDA | 45.93% | 28.68% | 37.26% | 58.48% | 45.38% |
| EPS Basic | 75.55% | -5.90% | 55.21% | 63.76% | 60.48% |
| Normalized Basic EPS | 77.23% | -10.68% | 54.16% | 66.00% | 56.04% |
| EPS Diluted | 75.55% | -5.90% | 55.21% | 63.76% | 60.48% |
| Normalized Diluted EPS | 77.23% | -10.68% | 54.16% | 66.00% | 56.04% |
| Average Basic Shares Outstanding | 262.93% | 43.70% | 42.20% | 30.93% | -98.83% |
| Average Diluted Shares Outstanding | 262.93% | 43.70% | 42.20% | 30.93% | -98.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |